Try our Advanced Search for more refined results
Life Sciences - April, 2006
43 articles
- E.U. Backs WTO Bid For Cheaper Drugs For Poor Nations
- PTO Application Changes To Hit Bio, Pharma Hardest
- Shire "Encouraged" By Settlement Talks Over Adderall
- Solutia Wins Six-Month Extension On Chapter 11 Plan
- P&G Case Underscores Trade Dress Challenges
- J&J Faces Growing Threat In Ditropan XL Litigation
- Tiny Biotech Wins Permanent Injunction Against Eli Lilly
- Branded Drug Cos. Paying Off Generics: FTC Report
- Austrian Court Hands Ranbaxy Lipitor Win
- Amgen Launches Preemptive Strike in Patent Battle
- FDA's "Holding On The Merits" Test
- One More ABB Unit Slides Into Chapter 11
- Plavix Deal Triggers More Antitrust Charges
- Court Removes Obstacle To Teva's Cholesterol Drug
- Study: Drug Companies Move To Deter Generics
- Dey Launches Suit Over Patent For Respiratory Aid
- Brussels Snapshot: Clifford Chance
- Dr. Reddy's Launches Allegra Generic
- Suits Nail Northfield Over Blood Substitute
- Wyeth Continues Battle Over Antidepressant Drug
- Medtronic Hits Kyphon With Patent Suit
- TiVo Prevails In DVR Suit With $74M Award
- Amgen Files ITC Complaint Over Roche Anemia Drug
- Class Action Targets St. Jude Medical
- E.C. Clears Way For Boston Scientific, Guidant Deal
- Merck Sues To Stop Manufacture Of Generic Fosamax
- CooperVision Takes Aim At Ciba Vision In Suits
- Bayer Hits Teva With Suit Over Eye Infection Drug
- Wyeth, Impax Head To Court Over Effexor
- Sanofi-Aventis' Lovenox Patent Restored on Appeal
- Generic Drug Makers Did Not Violate Antitrust Law: Jury
- Federal Circuit Orders Court To Hear Vitamin Suit
- SEC Probes Bankrupt Biotech Company
- Court Endorses Congoleum Insurance Settlement
- Mary Kay To Pay $40M Over Wrinkle Cream Patent
- J&J Sued By Rival Over Contact Lenses
- Guidant, Boston Scientific Take Heart In Merger Approval
- Acacia May Face Reexam Of Barcode Patent
- Mintz Levin Taps Silicon Valley, Acquires IP Boutique
- ABB Unit Finalizes Plan For Asbestos Claims
- Acacia Wins Settlement From Boston Scientific
- Appeals Court Affirms Sentence In Fraud Case
- SEC Targets Biovail Over Trading Issues